NCT06845813View on ClinicalTrials.gov

Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD6234

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 24, 2025

Primary Completion Date

January 8, 2026

Study Completion Date

January 8, 2026

Conditions
Renal Impairment
Interventions
DRUG

AZD6234

Dose 1

Trial Locations (4)

32808

RECRUITING

Research Site, Orlando

32809

RECRUITING

Research Site, Orlando

33618

WITHDRAWN

Research Site, Tampa

92630

RECRUITING

Research Site, Lake Forest

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY